Anthony Christopher Vernon - Publications

King's College (London), London, England, United Kingdom 
Neuroscience, schizophrenia, parkinson's disease

50 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Hanger B, Couch A, Rajendran L, Srivastava DP, Vernon AC. Emerging Developments in Human Induced Pluripotent Stem Cell-Derived Microglia: Implications for Modelling Psychiatric Disorders With a Neurodevelopmental Origin. Frontiers in Psychiatry. 11: 789. PMID 32848951 DOI: 10.3389/Fpsyt.2020.00789  0.345
2020 Andersen HG, Raghava JM, Svarer C, Wulff S, Johansen LB, Antonsen PK, Nielsen MØ, Rostrup E, Vernon AC, Jensen LT, Pinborg LH, Glenthøj BY, Ebdrup BH. Striatal Volume Increase After Six Weeks of Selective Dopamine D Receptor Blockade in First-Episode, Antipsychotic-Naïve Schizophrenia Patients. Frontiers in Neuroscience. 14: 484. PMID 32508577 DOI: 10.3389/Fnins.2020.00484  0.353
2020 Onwordi EC, Halff EF, Whitehurst T, Mansur A, Cotel MC, Wells L, Creeney H, Bonsall D, Rogdaki M, Shatalina E, Reis Marques T, Rabiner EA, Gunn RN, Natesan S, Vernon AC, et al. Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nature Communications. 11: 246. PMID 31937764 DOI: 10.1038/S41467-019-14122-0  0.344
2020 Fletcher EJR, Finlay CJ, Amor Lopez A, Crum WR, Vernon AC, Duty S. Neuroanatomical and Microglial Alterations in the Striatum of Levodopa-Treated, Dyskinetic Hemi-Parkinsonian Rats Frontiers in Neuroscience. 14. DOI: 10.3389/Fnins.2020.567222  0.372
2020 Peris-Yague A, Kiemes A, Cash D, Cotel M, Singh N, Vernon A, Modinos G. T209. EFFECTS OF CHRONIC HALOPERIDOL EXPOSURE ON [3H]RO15-4513 AND [3H]FLUMAZENIL GABA-A RECEPTOR BINDING SITES Schizophrenia Bulletin. 46: S312-S312. DOI: 10.1093/Schbul/Sbaa029.769  0.34
2020 Chika Onwordi E, Halff E, Whitehurst T, Mansur A, Cotel M, Wells L, Creeney H, Bonsall D, Rogdaki M, Shatalina E, Reis Marques T, Rabiner E, Gunn R, Natesan S, Vernon A, et al. O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS Schizophrenia Bulletin. 46: S28-S28. DOI: 10.1093/Schbul/Sbaa028.063  0.32
2019 Kuan WL, Stott K, He X, Wood TC, Yang S, Kwok JCF, Hall K, Zhao Y, Tietz O, Aigbirhio FI, Vernon AC, Barker RA. Systemic α-synuclein injection triggers selective neuronal pathology as seen in patients with Parkinson's disease. Molecular Psychiatry. PMID 31758091 DOI: 10.1038/S41380-019-0608-9  0.355
2019 Turkheimer FE, Selvaggi P, Mehta MA, Veronese M, Zelaya F, Dazzan P, Vernon AC. Normalizing the Abnormal: Do Antipsychotic Drugs Push the Cortex Into an Unsustainable Metabolic Envelope? Schizophrenia Bulletin. PMID 31755955 DOI: 10.1093/Schbul/Sbz119  0.336
2019 Doostdar N, Kim E, Grayson B, Harte MK, Neill JC, Vernon AC. Global brain volume reductions in a sub-chronic phencyclidine animal model for schizophrenia and their relationship to recognition memory. Journal of Psychopharmacology (Oxford, England). 269881119844196. PMID 31060435 DOI: 10.1177/0269881119844196  0.339
2019 Cotel M, Lindenmaier Z, Lenartowicz E, Natesan S, Lerch J, Vernon A. 179. Effects of Chronic Haloperidol Treatment on Brain Volume in a Rat Model in of Infection-Mediated Neurodevelopmental Disorders Biological Psychiatry. 85: S74. DOI: 10.1016/J.Biopsych.2019.03.193  0.341
2018 Murray KN, Edye ME, Manca M, Vernon AC, Oladipo JM, Fasolino V, Harte MK, Mason V, Grayson B, McHugh PC, Knuesel I, Prinssen EP, Hager R, Neill JC. Evolution of a maternal immune activation (mIA) model in rats: early developmental effects. Brain, Behavior, and Immunity. PMID 30218784 DOI: 10.1016/J.Bbi.2018.09.005  0.361
2018 Calevro A, Cotel MC, Natesan S, Modo M, Vernon AC, Mondelli V. Effects of chronic antipsychotic drug exposure on the expression of Translocator Protein and inflammatory markers in rat adipose tissue. Psychoneuroendocrinology. 95: 28-33. PMID 29793094 DOI: 10.1016/J.Psyneuen.2018.05.021  0.305
2018 Cotel M, Polacek R, Lenartowicz E, Natesan S, Cooper J, Vernon A. 40.3 MATERNAL IMMUNE ACTIVATION AND CHRONIC HALOPERIDOL INTERACT TO INCREASE MICROGLIAL ACTIVATION IN VIVO: DO ANTIPSYCHOTICS INFLAME THE BRAIN? Schizophrenia Bulletin. 44: S65-S65. DOI: 10.1093/Schbul/Sby014.166  0.304
2017 Hawkins PCT, Wood TC, Vernon AC, Bertolino A, Sambataro F, Dukart J, Merlo-Pich E, Risterucci C, Silber-Baumann H, Walsh E, Mazibuko N, Zelaya FO, Mehta MA. An investigation of regional cerebral blood flow and tissue structure changes after acute administration of antipsychotics in healthy male volunteers. Human Brain Mapping. PMID 29058358 DOI: 10.1002/Hbm.23844  0.334
2017 Amato D, Vernon AC, Papaleo F. Dopamine, the antipsychotic molecule: a perspective on mechanisms underlying antipsychotic response variability. Neuroscience and Biobehavioral Reviews. PMID 28970021 DOI: 10.1016/J.Neubiorev.2017.09.027  0.316
2017 Modo M, Crum WR, Gerwig M, Vernon AC, Patel P, Jackson MJ, Rose S, Jenner P, Iravani MM. Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's disease. Plos One. 12: e0180733. PMID 28738061 DOI: 10.1371/Journal.Pone.0180733  0.404
2017 Westphal R, Simmons C, Mesquita MB, Wood TC, Williams SC, Vernon AC, Cash D. Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson's disease. Plos One. 12: e0172394. PMID 28249008 DOI: 10.1371/Journal.Pone.0172394  0.397
2017 Notter T, Coughlin JM, Gschwind T, Weber-Stadlbauer U, Wang Y, Kassiou M, Vernon AC, Benke D, Pomper MG, Sawa A, Meyer U. Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia. Molecular Psychiatry. PMID 28093569 DOI: 10.1038/Mp.2016.248  0.336
2016 Crum WR, Sawiak SJ, Chege W, Cooper JD, C R Williams S, Vernon AC. Evolution of structural abnormalities in the rat brain following in utero exposure to maternal immune activation: a longitudinal in vivo MRI study. Brain, Behavior, and Immunity. PMID 27940258 DOI: 10.1016/J.Bbi.2016.12.008  0.361
2016 Pienaar IS, Vernon A, Winn P. The Cellular Diversity of the Pedunculopontine Nucleus: Relevance to Behavior in Health and Aspects of Parkinson's Disease. The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry. PMID 27932591 DOI: 10.1177/1073858416682471  0.311
2016 Wood TC, Simmons C, Hurley SA, Vernon AC, Torres J, Dell'Acqua F, Williams SC, Cash D. Whole-brain ex-vivo quantitative MRI of the cuprizone mouse model. Peerj. 4: e2632. PMID 27833805 DOI: 10.7717/Peerj.2632  0.302
2016 Richetto J, Chesters R, Cattaneo A, Labouesse MA, Gutierrez AM, Wood TC, Luoni A, Meyer U, Vernon A, Riva MA. Genome-Wide Transcriptional Profiling and Structural Magnetic Resonance Imaging in the Maternal Immune Activation Model of Neurodevelopmental Disorders. Cerebral Cortex (New York, N.Y. : 1991). PMID 27797829 DOI: 10.1093/Cercor/Bhw320  0.316
2016 Amato D, Beasley CL, Hahn MK, Vernon AC. Neuroadaptations to antipsychotic drugs: insights from pre-clinical and human post-mortem studies. Neuroscience and Biobehavioral Reviews. PMID 27756689 DOI: 10.1016/J.Neubiorev.2016.10.004  0.361
2016 Hamburg H, Trossbach SV, Bader V, Chwiesko C, Kipar A, Sauvage M, Crum WR, Vernon AC, Bidmon HJ, Korth C. Simultaneous effects on parvalbumin-positive interneuron and dopaminergic system development in a transgenic rat model for sporadic schizophrenia. Scientific Reports. 6: 34946. PMID 27721451 DOI: 10.1038/Srep34946  0.362
2016 Crum WR, Danckaers F, Huysmans T, Cotel MC, Natesan S, Modo MM, Sijbers J, Williams SC, Kapur S, Vernon AC. Chronic exposure to haloperidol and olanzapine leads to common and divergent shape changes in the rat hippocampus in the absence of grey-matter volume loss. Psychological Medicine. 1-13. PMID 27516217 DOI: 10.1017/S0033291716001768  0.351
2016 Westphal R, Sumiyoshi A, Simmons C, Mesquita M, Wood TC, Williams SC, Vernon AC, Cash D. Characterization of grey matter atrophy following 6-hydroxydopamine lesion of the nigrostriatal system. Neuroscience. PMID 27506141 DOI: 10.1016/J.Neuroscience.2016.07.046  0.392
2015 Vernon AC, So PW, Lythgoe DJ, Chege W, Cooper JD, Williams SC, Kapur S. Longitudinal in vivo maturational changes of metabolites in the prefrontal cortex of rats exposed to polyinosinic-polycytidylic acid in utero. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 26475576 DOI: 10.1016/J.Euroneuro.2015.09.022  0.353
2015 Cotel MC, Lenartowicz EM, Natesan S, Modo MM, Cooper JD, Williams SC, Kapur S, Vernon AC. Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 26321204 DOI: 10.1016/J.Euroneuro.2015.08.004  0.388
2015 Harrison IF, Crum WR, Vernon AC, Dexter DT. Neurorestoration Induced by the HDAC Inhibitor Sodium Valproate in the Lactacystin Model of Parkinson's is Associated with Histone Acetylation and Upregulation of Neurotrophic Factors. British Journal of Pharmacology. PMID 26040297 DOI: 10.1111/Bph.13208  0.664
2015 Turkheimer FE, Leech R, Expert P, Lord LD, Vernon AC. The brain's code and its canonical computational motifs. From sensory cortex to the default mode network: A multi-scale model of brain function in health and disease. Neuroscience and Biobehavioral Reviews. 55: 211-22. PMID 25956253 DOI: 10.1016/J.Neubiorev.2015.04.014  0.31
2014 Finlay CJ, Duty S, Vernon AC. Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies. Frontiers in Neurology. 5: 95. PMID 24971074 DOI: 10.3389/Fneur.2014.00095  0.376
2014 Vernon AC, Crum WR, Lerch JP, Chege W, Natesan S, Modo M, Cooper JD, Williams SC, Kapur S. Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs-linking magnetic resonance imaging findings to cellular pathology. Biological Psychiatry. 75: 982-90. PMID 24143881 DOI: 10.1016/J.Biopsych.2013.09.012  0.37
2014 Vernon AC, Natesan S, Chege W, Crum WR, Modo M, Cooper JD, Williams SC, Kapur S. IMPACT OF CHRONIC ANTIPSYCHOTIC DRUG TREATMENT ON BRAIN MORPHOLOGY: A CAUSE FOR CONCERN? Schizophrenia Research. 153: S69-S70. DOI: 10.1016/S0920-9964(14)70225-7  0.328
2013 Vernon AC, Hajek T. Effects of lithium on magnetic resonance imaging signal might not preclude increases in brain volume after chronic lithium treatment Biological Psychiatry. 74. PMID 23998561 DOI: 10.1016/J.Biopsych.2012.12.028  0.322
2012 Vernon AC, Natesan S, Crum WR, Cooper JD, Modo M, Williams SC, Kapur S. Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. Biological Psychiatry. 71: 855-63. PMID 22244831 DOI: 10.1016/J.Biopsych.2011.12.004  0.354
2012 Vernon AC, Modo M. Do levodopa treatments modify the morphology of the parkinsonian brain? Movement Disorders. 27: 166-167. PMID 22076912 DOI: 10.1002/Mds.24018  0.312
2011 Vernon AC, Smith EJ, Stevanato L, Modo M. Selective activation of metabotropic glutamate receptor 7 induces inhibition of cellular proliferation and promotes astrocyte differentiation of ventral mesencephalon human neural stem/progenitor cells. Neurochemistry International. 59: 421-31. PMID 21624409 DOI: 10.1016/J.Neuint.2011.04.001  0.32
2011 Vernon AC, Crum WR, Johansson SM, Modo M. Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease. Plos One. 6: e17269. PMID 21364887 DOI: 10.1371/Journal.Pone.0017269  0.35
2011 Vernon AC, Modo M. Non-invasive MR imaging of neurodegeneration in a rodent model of Parkinson's disease. Methods in Molecular Biology (Clifton, N.J.). 711: 487-510. PMID 21279619 DOI: 10.1007/978-1-61737-992-5_25  0.376
2011 Vernon AC, Natesan S, Modo M, Kapur S. Effect of chronic antipsychotic treatment on brain structure: A serial magnetic resonance imaging study with ex vivo and postmortem confirmation Biological Psychiatry. 69: 936-944. PMID 21195390 DOI: 10.1016/J.Biopsych.2010.11.010  0.373
2011 Vernon A, Natesan S, Modo M, Kapur S. P.3.d.006 Contrasting effects of haloperidol and lithium on rat brain structure: a serial MRI study European Neuropsychopharmacology. 21: S509. DOI: 10.1016/S0924-977X(11)70828-8  0.312
2010 Chan H, Paur H, Vernon AC, Zabarsky V, Datla KP, Croucher MJ, Dexter DT. Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease. Parkinson's Disease. 2010. PMID 20948891 DOI: 10.4061/2010/190450  0.607
2010 Vernon AC, Ballard C, Modo M. Neuroimaging for Lewy body disease: Is the in vivo molecular imaging of ?-synuclein neuropathology required and feasible? Brain Research Reviews. 65: 28-55. PMID 20685363 DOI: 10.1016/J.Brainresrev.2010.05.006  0.32
2010 Vernon AC, Johansson SM, Modo MM. Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease. Bmc Neuroscience. 11: 1. PMID 20051106 DOI: 10.1186/1471-2202-11-1  0.379
2009 Vernon AC. Mice with reduced vesicular monoamine storage content display nonmotor features of Parkinson's disease Journal of Neuroscience. 29: 12842-12844. PMID 19828798 DOI: 10.1523/Jneurosci.4156-09.2009  0.334
2008 Vernon AC, Croucher MJ, Dexter DT. Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's model. Neuroreport. 19: 475-8. PMID 18287950 DOI: 10.1097/Wnr.0B013E3282F602Df  0.593
2007 Vernon AC, Zbarsky V, Datla KP, Croucher MJ, Dexter DT. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. Journal of Neurochemistry. 103: 1075-91. PMID 17714448 DOI: 10.1111/J.1471-4159.2007.04860.X  0.619
2007 Vernon AC, Zbarsky V, Datla KP, Dexter DT, Croucher MJ. Selective activation of group III metabotropic glutamate receptors by L-(+)-2-amino-4-phosphonobutryic acid protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. The Journal of Pharmacology and Experimental Therapeutics. 320: 397-409. PMID 17012606 DOI: 10.1124/Jpet.106.108159  0.6
2005 Vernon AC, Palmer S, Datla KP, Zbarsky V, Croucher MJ, Dexter DT. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. The European Journal of Neuroscience. 22: 1799-806. PMID 16197521 DOI: 10.1111/J.1460-9568.2005.04362.X  0.61
Show low-probability matches.